<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376401</url>
  </required_header>
  <id_info>
    <org_study_id>BenVelPres</org_study_id>
    <nct_id>NCT01376401</nct_id>
  </id_info>
  <brief_title>Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mundipharma Pharmaceuticals B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol corresponds to an open-label national phase II, multicenter, to assess efficacy&#xD;
      (in terms of response rate and CR) and toxicity of bendamustine, bortezomib and prednisone&#xD;
      (BVP) in 60 patients newly diagnosed MM. Patients in the absence of disease progression or&#xD;
      unacceptable toxicity receive up to 9 cycles of BVP. The patients eligible for autologous&#xD;
      transplant receive four cycles of BVP, hematopoietic stem cell collection and administration&#xD;
      of two cycles BVP over followed by autologous transplant.&#xD;
&#xD;
      In addition to the overall response rates, will also be analyzed time to progression (TTP),&#xD;
      progression-free survival (PFS) and overall survival.&#xD;
&#xD;
      Finally, the results will be compared with BVP with those obtained in 120 patients included&#xD;
      in our protocol VMP GEM10MAS65.&#xD;
&#xD;
      Patients will be evaluated at scheduled visits up to 3 periods of study:&#xD;
&#xD;
      pretreatment, treatment and monitoring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients included in the study will receive a 6 week cycle consisting of Bendamustine&#xD;
      administered IV at doses of 90 mg/m2 on days 1 and 4 of the first cycle and days 1 and 8 in&#xD;
      subsequent cycles in combination with Bortezomib as a bolus dose of 1.3 mg/m2 on days 1, 4,&#xD;
      8, 11, 22, 25, 29 and 32, and oral prednisone at doses of 60 mg/m2, during the first four&#xD;
      days of each cycle.&#xD;
&#xD;
      Then, patients will receive eight additional cycles of 5-week . The same pattern consisting&#xD;
      of bendamustine and prednisone but bortezomib is administered as an intravenous bolus dose of&#xD;
      1.3 mg/m2 on days 1, 8, 15 and 22.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in terms of response rate and complete response rate (CR and near CR)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety in terms of toxicity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progresion</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progresion free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient age greater than or equal to 18 at the time of signing Informed consent&#xD;
&#xD;
          -  Patient who has voluntarily signed informed consent before conduct of the trial any&#xD;
             evidence that is not part of care normal patients, with the knowledge of the patient&#xD;
             that can leave the trial at any time he want&#xD;
&#xD;
          -  Patient able, in the opinion of the physician to comply with the visitation schedule&#xD;
             and other requirements of the protocol&#xD;
&#xD;
          -  Patient newly diagnosed symptomatic multiple myeloma based on standard criteria and&#xD;
             has not received any previous treatment of chemotherapy for MM.&#xD;
&#xD;
          -  Patients with newly diagnosed multiple myeloma, secretory, or oligosecretor or not&#xD;
             secretor if it has soft tissue plasmacytomas.&#xD;
&#xD;
          -  Patients with non-secretory MM oligosecretor or without white tissue plasmacytomas be&#xD;
             excluded to keep a group of patients with characteristics similar to the previous&#xD;
             study with which we compare the results.&#xD;
&#xD;
          -  Patients with measurable disease, defined by the following criteria:&#xD;
&#xD;
        For MM secreting measurable disease is defined as any value quantifiable serum monoclonal&#xD;
        protein (≥ 1g/dl) and where applicable, a light chain excretion in urine ≥ 200 mg/24 hours.&#xD;
        For Multiple Myeloma oligosecretor or secreting measurable disease defined by the presence&#xD;
        of soft tissue plasmacytomas (not bone) determined by clinical examination or radiographic&#xD;
        methods (eg MRI, CT-Scan)&#xD;
&#xD;
          -  ECOG PS ≤ 2&#xD;
&#xD;
          -  Expectations of life than 3 months.&#xD;
&#xD;
          -  The patient has the following laboratory values within 28 days before the baseline&#xD;
             visit:&#xD;
&#xD;
        Platelet count ≥ 100 x 109 / L, hemoglobin ≥ 8.0g/dL and absolute neutrophil count (ANC) ≥&#xD;
        1.5 x 109 / L; allowed counts under if they are clearly due to a bone marrow infiltration&#xD;
        by MM.&#xD;
&#xD;
        Corrected serum calcium &lt;14mg/dL. Aspartate transaminase (AST) ≤ 2.5 x upper limit of&#xD;
        normal(LSN) Alanine aminotransferase (ALT) ≤ 2.5 x ULN Total bilirubin within normal limits&#xD;
        Serum creatinine &lt;2 mg / dL&#xD;
&#xD;
        - Patients of childbearing potential must use effective contraception during duration of&#xD;
        the study and up to 6 months after completion of treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has previously received treatment for multiple myeloma with Pulse steroids&#xD;
             except for some emergency that requires it before start of induction therapy,&#xD;
             administration of bisphosphonates or radiation therapy, or analgesic due to the&#xD;
             presence of plasmacytomas, which require it for some urgency.&#xD;
&#xD;
          -  Patients with non-measurable disease.&#xD;
&#xD;
          -  Patient with peripheral neuropathy grade ³ 2 within 14 days prior to its inclusion in&#xD;
             the trial&#xD;
&#xD;
          -  Patients with hypersensitivity to bortezomib, boric acid, or bendamustine mannitol&#xD;
&#xD;
          -  Patient to be known carrier of the virus HIV (human immunodeficiency) surface antigen&#xD;
             of hepatitis B virus or who has active infection virus hepatitis C.&#xD;
&#xD;
          -  Patient who has had a myocardial infarction within 6 months prior to inclusion in the&#xD;
             clinical trial or has a functional class III or IV according to the New York Heart&#xD;
             Association (NYHA) heart failure, uncontrolled angina, uncontrolled ventricular&#xD;
             arrhythmias or acute ischemia detected electrocardiographically or conduction system&#xD;
             disorders.&#xD;
&#xD;
          -  Patient who has received any investigational agent within 30 days prior their&#xD;
             inclusion or is currently in another clinical trial or receiving any investigational&#xD;
             agent&#xD;
&#xD;
          -  Patient undergoing major surgery within 30 days before inclusion in the study&#xD;
&#xD;
          -  Patient pregnant or breastfeeding&#xD;
&#xD;
          -  Patients with acute diffuse infiltrative pulmonary disease and / or disease&#xD;
             pericardium&#xD;
&#xD;
          -  History of other malignancies after different myeloma (except for basal or squamous&#xD;
             cell carcinoma of the skin or carcinoma in situ of the cervix or breast) to unless the&#xD;
             patient is free of the disease beyond 5 years&#xD;
&#xD;
          -  Hypertension arterial or poorly controlled diabetes mellitus or any other disease&#xD;
             severe organ involving an unreasonable risk to the patient&#xD;
&#xD;
          -  Any psychiatric disorder that interferes with comprehension of consent informed or&#xD;
             prevent the normal discharge that requires participation in this trial&#xD;
&#xD;
          -  Patients with major psychiatric history.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut català d'Oncología</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Internacional</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://aehh.org</url>
    <description>Spanish Association of Hematology</description>
  </link>
  <link>
    <url>http://www.trialformsupport.com</url>
    <description>CRO</description>
  </link>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>June 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>May 16, 2016</last_update_submitted>
  <last_update_submitted_qc>May 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

